Distinct effects of asthma and COPD comorbidity on disease expression and outcome in patients with COVID‐19

Male 0303 health sciences SARS-CoV-2 Immunology COVID-19 Comorbidity Middle Aged Asthma 3. Good health Pulmonary Disease, Chronic Obstructive 03 medical and health sciences Prevalence Immunology and Allergy Humans Female Angiotensin-Converting Enzyme 2 Aged
DOI: 10.1111/all.14517 Publication Date: 2020-07-27T15:35:55Z
ABSTRACT
AbstractBackgroundThe impacts of chronic airway diseases on coronavirus disease 2019 (COVID‐19) are far from understood.ObjectiveTo explore the influence of asthma and chronic obstructive pulmonary disease (COPD) comorbidity on disease expression and outcomes, and the potential underlying mechanisms in COVID‐19 patients.MethodsA total of 961 hospitalized COVID‐19 patients with a definite clinical outcome (death or discharge) were retrospectively enrolled. Demographic and clinical information were extracted from the medical records. Lung tissue sections from patients suffering from lung cancer were used for immunohistochemistry study of angiotensin‐converting enzyme II (ACE2) expression. BEAS‐2B cell line was stimulated with various cytokines.ResultsIn this cohort, 21 subjects (2.2%) had COPD and 22 (2.3%) had asthma. After adjusting for confounding factors, COPD patients had higher risk of developing severe illness (OR: 23.433; 95% CI 1.525‐360.135; P < .01) and acute respiratory distress syndrome (OR: 19.762; 95% CI 1.461‐267.369; P = .025) than asthmatics. COPD patients, particularly those with severe COVID‐19, had lower counts of CD4+ T and CD8+ T cells and B cells and higher levels of TNF‐α, IL‐2 receptor, IL‐10, IL‐8, and IL‐6 than asthmatics. COPD patients had increased, whereas asthmatics had decreased ACE2 protein expression in lower airways, compared with that in control subjects without asthma and COPD. IL‐4 and IL‐13 downregulated, but TNF‐α, IL‐12, and IL‐17A upregulated ACE2 expression in BEAS‐2B cells.ConclusionPatients with asthma and COPD likely have different risk of severe COVID‐19, which may be associated with different ACE2 expression.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (48)
CITATIONS (119)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....